Elias Tueni
About
In The Last Decade
Elias Tueni
23 papers receiving 532 citations
Peers
Comparison fields: 5 of 79
- Oncology 355
- Pulmonary and Respiratory Medicine 244
- Otorhinolaryngology 167
- Surgery 143
- Molecular Biology 83
Countries citing papers authored by Elias Tueni
This map shows the geographic impact of Elias Tueni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elias Tueni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elias Tueni more than expected).
Fields of papers citing papers by Elias Tueni
This network shows the impact of papers produced by Elias Tueni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elias Tueni. The network helps show where Elias Tueni may publish in the future.
Co-authorship network of co-authors of Elias Tueni
This figure shows the co-authorship network connecting the top 25 collaborators of Elias Tueni. A scholar is included among the top collaborators of Elias Tueni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elias Tueni. Elias Tueni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 27 | |
| 3 | 8 | |
| 4 | 19 | |
| 5 | 16 | |
| 6 | 12 | |
| 7 | 210 | |
| 8 | 115 | |
| 9 | The use of recombinant human granulocyte-macrophage colony-stimulating factor with combination chemotherapy in the treatment of advanced adult soft-tissue sarcomas: early results from the EORTC Soft-Tissue and Bone Sarcoma Group. | 7 |
| 10 | A phase I study of Taxotere (RP 56976 NSC 628503) administered as a one hour intravenous infusion on a weekly basis | 12 |
| 11 | 8 | |
| 12 | 28 | |
| 13 | In vitro activity of bleomycin, tallysomycin S10b, and liblomycin against fresh human tumor cells. | 6 |
| 14 | 3 | |
| 15 | Local postoperative morbidity following pre-operative irradiation in locally advanced breast cancer. | 35 |
| 16 | 10 | |
| 17 | 7 | |
| 18 | 5 | |
| 19 | 12 | |
| 20 | Phase I trial with oral menogaril (MEN; NSC 269148) | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.